Additionally, in contrast to the existing glioma biomarkers (such as IDH mutation, 1p/19q code deletion, TERT promoter mutation, H3F3A mutation, etc.)and previous studies on glioma dephosphorylation, the novelty of this study is that it has been experimentally verified that CDC25A influences the TMZ resistance of glioma U251 and LN229 cells, potentially providing a reference for the clinical treatment of glioma patients with TMZ. This evidence concerns the gene CDC25A and central nervous system cancer.